Twist Bioscience Corp (TWST) saw its stock price plummet by 5.20% in Tuesday's trading session, following a significant price target cut by JP Morgan analysts.
The sharp decline came after JP Morgan lowered its price target for Twist Bioscience from $40 to $33, maintaining an "Underweight" rating on the stock. This reduction in the price target suggests that the investment bank has become more pessimistic about the company's near-term prospects, which likely triggered a sell-off among investors.
While JP Morgan's downgrade seems to be the primary driver of the stock's decline, it's worth noting that Guggenheim maintained its price target for Twist Bioscience at $50 per share. This conflicting view from another analyst firm highlights the divergent opinions on the company's future performance. Investors appear to be giving more weight to JP Morgan's bearish stance in the short term, as reflected in the significant stock price drop.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.